2.48 USD
▲+0.03+1.22%
盘后 4.02 0.00%
2026-11-20
市值
$138.30M
市盈率
6.94
EPS
-1.13
股息率
—
52 周区间
2.09 – 7.65
成交量
1.22M
Beta
1.48
目标价
15.44
52W 低 2.0952W 高 7.65
价格走势
公司简介
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor...